Gerard Ian Evan FRS, FMedSci (born 17 August 1955) is a British biologist and, since May 2022, Professor of Cancer Biology at King's College London and a principal group leader in the Francis Crick Institute. Prior to this he was Sir William Dunn Professor of Biochemistry and Head of Biochemistry at the University of Cambridge (2009-2022).[11][13]
Gerard Evan | |
|---|---|
| Born | 17 August 1955[10] |
| Alma mater | St Peter's College, Oxford King's College, Cambridge[10] |
| Known for | Disease Models & Mechanisms |
| Awards | Fellow of the Royal Society (2004) FMedSci (1999)[1] PhD (1982) |
| Scientific career | |
| Fields | Cancer[2][3][4][5][6][7] Disease biology Myc regulator gene[8] p53 tumour suppressor[9] |
| Institutions | University of Oxford University of Cambridge UCSF[10][11] Cancer Research UK[12] Ensemble Therapeutics |
| Thesis | Monoclonal antibodies as reagents for the analysis of cell surfaces (1982) |
| Website | www labmed |
Education
editEvan was educated at St Peter's College, Oxford, where he studied Biochemistry, and King's College, Cambridge, where he was awarded his PhD in 1982 for research using Monoclonal antibodies.[10][14]
Research
editEvan does research to the determine the molecular basis of cancer.[15][16][17][18][19][20][21][22]
Career
editPrior to Cambridge, Evan was Royal Society Napier Professor at University College London and the Imperial Cancer Research Fund (1988-99), then Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology, at University of California, San Francisco (1999-2011).
References
edit- ^ http://www.acmedsci.ac.uk/p59fid5303.html [dead link]
- ^ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation". Molecular and Cellular Biology. 29 (19): 5306–5315. doi:10.1128/MCB.01745-08. PMC 2747972. PMID 19635809.
- ^ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors". Genes & Development. 25 (16): 1746–1757. doi:10.1101/gad.16722111. PMC 3165938. PMID 21852537.
- ^ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo". Cancer Cell. 14 (6): 447–457. doi:10.1016/j.ccr.2008.10.018. PMC 2723751. PMID 19061836.
- ^ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment". Genes & Development. 25 (9): 907–916. doi:10.1101/gad.2038411. PMC 3084025. PMID 21478273.
- ^ Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan". Disease Models and Mechanisms. 1 (2–3): 90–93. doi:10.1242/dmm.001396. PMC 2562192. PMID 19048069.
- ^ Anon (2008). "Making the paper: Gerard Evan". Nature. 455 (7213): xiii. doi:10.1038/7213xiiia. S2CID 4410691.
- ^ Evan, G. (2012). "Taking a Back Door to Target Myc". Science. 335 (6066): 293–294. Bibcode:2012Sci...335..293E. doi:10.1126/science.1217819. PMID 22267799. S2CID 26445434.
- ^ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer. 9 (11): 821–829. doi:10.1038/nrc2728. PMID 19776747. S2CID 29250930.
- ^ a b c d "EVAN, Prof. Gerard Ian". Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press.(subscription required)
- ^ a b "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci". Archived from the original on 1 June 2013.
- ^ "Gerard Evan : Cancer Research UK". Archived from the original on 10 March 2014.
- ^ Gerard Evan publications indexed by Microsoft Academic
- ^ Evan, Gerard (1982). Monoclonal antibodies as reagents for the analysis of cell surfaces (PhD thesis). University of Cambridge.
- ^ Christophorou, M. A.; Ringshausen, I.; Finch, A. J.; Swigart, L. B.; Evan, G. I. (2006). "The pathological response to DNA damage does not contribute to p53-mediated tumour suppression". Nature. 443 (7108): 214–217. Bibcode:2006Natur.443..214C. doi:10.1038/nature05077. PMID 16957739. S2CID 4417336.
- ^ Junttila, M. R.; Karnezis, A. N.; Garcia, D.; Madriles, F.; Kortlever, R. M.; Rostker, F.; Brown Swigart, L.; Pham, D. M.; Seo, Y.; Evan, G. I.; Martins, C. P. (2010). "Selective activation of p53-mediated tumour suppression in high-grade tumours". Nature. 468 (7323): 567–571. Bibcode:2010Natur.468..567J. doi:10.1038/nature09526. PMC 3011233. PMID 21107427.
- ^ Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. (2008). "Modelling Myc inhibition as a cancer therapy". Nature. 455 (7213): 679–683. Bibcode:2008Natur.455..679S. doi:10.1038/nature07260. PMC 4485609. PMID 18716624.
- ^ Evan, Gerard I.; Vousden, Karen H. (2001). "Proliferation, cell cycle and apoptosis in cancer". Nature. 411 (6835): 342–348. Bibcode:2001Natur.411..342E. doi:10.1038/35077213. PMID 11357141. S2CID 4414024.
- ^ Hueber, A. O.; Zörnig, M.; Lyon, D.; Suda, T.; Nagata, S.; Evan, G. I. (1997). "Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis". Science. 278 (5341): 1305–1309. Bibcode:1997Sci...278.1305H. doi:10.1126/science.278.5341.1305. PMID 9360929.
- ^ Chittenden, T.; Harrington, E. A.; O'Connor, R.; Remington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. (1995). "Induction of apoptosis by the Bcl-2 homologue Bak". Nature. 374 (6524): 733–736. Bibcode:1995Natur.374..733C. doi:10.1038/374733a0. PMID 7715730. S2CID 4315947.
- ^ Fanidi, A.; Harrington, E. A.; Evan, G. I. (1992). "Cooperative interaction between c-myc and bcl-2 proto-oncogenes". Nature. 359 (6395): 554–556. Bibcode:1992Natur.359..554F. doi:10.1038/359554a0. PMID 1406976. S2CID 4247014.
- ^ Amati, B.; Dalton, S.; Brooks, M. W.; Littlewood, T. D.; Evan, G. I.; Land, H. (1992). "Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max". Nature. 359 (6394): 423–426. Bibcode:1992Natur.359..423A. doi:10.1038/359423a0. PMID 1406955. S2CID 4362486.